Loading...
Loading...
GLUE| Name | Value |
|---|---|
| Revenues | 8.8M |
| Cost of Revenue | 1.8M |
| Gross Profit | 6.9M |
| Operating Expense | 33.0M |
| Operating I/L | -34.9M |
| Other Income/Expense | 1.6M |
| Interest Income | 2.4M |
| Pretax | -33.3M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -33.3M |
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company specializing in the development of small molecule precision medicines that target specific proteins for degradation, leveraging the body's natural mechanisms. Their pipeline includes an oral molecular glue degrader for GSPT1, a translational termination factor, and degron-containing protein for Myc-driven cancers, as well as developments for CDK2, NEK7, VAV1, and BCL11A targeting various diseases and conditions.
